Granules India Ltd

Granules India Limited is a large-scale vertically-integrated company found in March 1991. It manufactures active pharmaceutical ingredients, pharmaceutical formulation intermediates, and finished dosages. The company has a strong presence in off-patent drugs, first-line defence products such as Paracetamol, Ibuprofen, Metformin, and Guaifenesin, as well as a global presence in over 80 countries and 250 customers. It also has a 15,000 sq. ft. research center in Pragathi Nagar, Hyderabad and has completed expansion projects in Gagillapur and Visakhapatnam. In FY 2014-15, the company crossed Rs 1200 crore in revenue, made its first acquisition, and increased its PFI capacity by 4000 tons / annum. During 2015-16 it initiated construction of 7000 TPA Metformin and 2000 TPA Guaifenesin API block, and has a total of 22 EDMF/CEP and 44 ANDA filings with US FDA. In FY 2017 the company received Establishment Inspection Report from US FDA for its Jeedimetla plant and license from the Drug Enforcement Agency for its Virginia facility. In FY 2018, it crossed Rs 1400 crore in revenue and initiated commercial production of Metaformin and Paracetamol API at its Bonthapally facility. The company also successfully received 7 ANDAs approvals from US FDA. In FY 2019, Granules India initiated buyback programme, with the Board of Directors approving a buyback of up to 12.5 million equity shares on 21 January 2020. The Company has divested its entire 50% shareholding in GranulesBiocause Pharmaceutical Co. Ltd and Granules Omnichem Private Ltd. for a consideration of Rs 111.2 crore. During the year 2021, Granules Pharmaceuticals Inc. announced a voluntary recall of 12 batches of Metformin Hydrochloride Extended Release tablets USP 750 mg, out of caution. In 2022, the Company completed the largest single manufacturing site for Multiple Unit Pellet System MUPS at its Gagillapur facility and capacity expansion for manufacturing multiple APIs at Unit V Visakhapatnam. In a span of over 30 years, Granules India has firmly established its leadership in the off-patent drugs segment, and a strong presence in first line of defense products, creating a global presence in over 80 countries, servicing over 250 customers and filing 66 EDMF/CE

Revenue: ₹1,457.43Cr as on March 2026 (Q4 FY26)
Net Profit: ₹201.57Cr as on March 2026 (Q4 FY26)
Listing date: 20 Jun, 2005
Chairperson Name: C Krishna Prasad